AGIX updates Phase II CART-1 data

AtheroGenics (AGIX) said its AGI-1067 met the primary endpoint of greater

Read the full 118 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE